A similar integration of serum proteomic biomarkers for screening in patients with an increased cancer risk based on their family history or inherited disorders such as Lynch Syndrome characterized by mutations in genes such as the DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS1, PMS2) [117], TP53-associated cancers in the case of Li–Fraumeni syndrome, and BRCA1/2 for breast cancer is currently lacking. This evidence concerns the gene BRCA1 and cancer.